Can two diabetes drugs save kidneys after cancer surgery?
NCT ID NCT06818305
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether two drugs, finerenone and empagliflozin, can slow kidney function decline in people at high risk for chronic kidney disease after having a kidney removed for cancer. Ten participants took one or both drugs or no drug for a year. The trial was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Finerenone and Empagliflozin (drugs)
What this could lead to
If successful, this could point toward a way to slow kidney function loss in patients who had a kidney removed due to cancer.
What could go wrong
This is a very small, early-phase study (only 10 participants) that was terminated, so results are limited. The drugs may not work better than standard care and carry risks like high potassium, low blood pressure, or infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing
Nanjing, Jiangsu, 210000, China